{
  "actions": [
    {
      "acted_at": "2006-07-27", 
      "references": [
        {
          "reference": "CR E1569-1570", 
          "type": null
        }
      ], 
      "text": "Sponsor introductory remarks on measure.", 
      "type": "action"
    }, 
    {
      "acted_at": "2006-07-27", 
      "committee": "House Committee on Energy and Commerce", 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2006-08-01", 
      "in_committee": "House Committee on Energy and Commerce", 
      "references": [], 
      "subcommittee": "Health", 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr5922-109", 
  "bill_type": "hr", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }
  ], 
  "congress": "109", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2006-07-27", 
  "number": "5922", 
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs, to establish whistleblower protections for certain individuals, and for other purposes.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "SAFE Drug Act", 
  "sponsor": {
    "district": "7", 
    "name": "Markey, Edward J.", 
    "state": "MA", 
    "thomas_id": "00735", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2006-07-27", 
  "subjects": [
    "Actions and defenses", 
    "Administrative remedies", 
    "Civil rights and liberties, minority issues", 
    "Commerce", 
    "Communication in science", 
    "Congressional reporting requirements", 
    "Damages", 
    "Deceptive advertising", 
    "Department of Health and Human Services", 
    "Department of Labor", 
    "Disciplining of employees", 
    "Discrimination in employment", 
    "Dismissal of employees", 
    "Drug approvals", 
    "Drug industry", 
    "Drugs", 
    "Federal employees", 
    "Federal officials", 
    "Fines (Penalties)", 
    "Food and Drug Administration (FDA)", 
    "Government operations and politics", 
    "Health", 
    "Informed consent (Medical law)", 
    "Labeling", 
    "Labor and employment", 
    "Law", 
    "Legal fees", 
    "Marketing", 
    "Pharmaceutical research", 
    "Punitive damages", 
    "Science, technology, communications", 
    "Scientists in government", 
    "Wage restitution", 
    "Whistle blowing"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2006-07-27", 
    "text": "Swift Approval, Full Evaluation Drug Act or the SAFE Drug Act - Amends the Federal Food, Drug, and Cosmetic Act to: (1) authorize the Secretary of Health and Human Services, upon receipt of evidence regarding the safety or lack of effectiveness of an approved drug, to order studies of such drug (postmarket studies) and place restrictions on the distribution or use of such drug during such studies; (2) require postmarket studies as a condition of approval of a new drug; (3) impose civil penalties for distributing misbranded or adulterated drugs or for failing to compete a required postmarket study; (4) label a drug misbranded if a drug manufacturer fails to make required postmarket labeling changes; (5) grant officers and employees of the Food and Drug Administration the right to publish or present data unless such data is subject to federal export control or national security laws or is proprietary information; and (6) require the Secretary to submit biennial reports to Congress on approved drug applications supported by non-inferiority studies and on postmarket studies. Extends protections to individuals (whistleblowers) who provide information of illegal activity to government officials."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "SAFE Drug Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Swift Approval, Full Evaluation Drug Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs, to establish whistleblower protections for certain individuals, and for other purposes.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-07-19T19:56:45-04:00"
}